Advances in Chronic Kidney Disease
Volume 14, Issue 1 , Pages 27-36 , January 2007

Bone Health in Chronic Kidney Disease–Mineral and Bone Disease

  • Anca Gal-Moscovici

      Affiliations

    • Evanston Northwestern Healthcare, Northwestern University Feinberg School of Medicine, Evanston, IL
    • Hadassah Hospital Medical Center, Hebrew University, Ein-Karem, Jerusalem, Israel
    • ,
  • Stuart M. Sprague

      Affiliations

    • Evanston Northwestern Healthcare, Northwestern University Feinberg School of Medicine, Evanston, IL
    • Corresponding Author InformationAddress correspondence to Stuart M. Sprague, DO, Division of Nephrology and Hypertension, Evanston Northwestern Healthcare, 2650 Ridge Avenue, Evanston, IL 60201.

References 

  1. Block GA, Klassen PS, Lazarus JM, et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15:2208–2218
  2. Malluche HH, Mawad H, Monier-Faugere MC. The importance of bone health in end-stage renal disease: Out of the frying pan, into the fire?. Nephrol Dial Transplant. 2004;19(Suppl 1):i9–i13
  3. Moe S, Drueke T, Cunningham J, et al. Definition, evaluation, and classification of renal osteodystrophy: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2006;69:1945–1953
  4. Sherrard DJ, Hercz G, Pei Y, et al. The spectrum of bone disease in end-stage renal failure—An evolving disorder. Kidney Int. 1993;43:436–442
  5. Barreto FC, Barreto DV, Moyses RM, et al. Osteoporosis in hemodialysis patients revisited by bone histomorphometry: A new insight into an old problem. Kidney Int. 2006;69:1852–1857
  6. Parfitt AM, Drezner MK, Glorieux FH, et al. Bone histomorphometry: standardization of nomenclature, symbols, and units (Report of the ASBMR Histomorphometry Nomenclature Committee). J Bone Miner Res. 1987;2:595–610
  7. Hutchison AJ, Whitehouse RW, Boulton HF, et al. Correlation of bone histology with parathyroid hormone, vitamin D3, and radiology in end-stage renal disease. Kidney Int. 1993;44:1071–1077
  8. Qi Q, Monier-Faugere MC, Geng Z, et al. Predictive value of serum parathyroid hormone levels for bone turnover in patients on chronic maintenance dialysis. Am J Kidney Dis. 1995;26:622–631
  9. Lehmann G, Stein G, Huller M, et al. Specific measurement of PTH (1-84) in various forms of renal osteodystrophy (ROD) as assessed by bone histomorphometry. Kidney Int. 2005;68:1206–1214
  10. Coen G, Bonucci E, Ballanti P, et al. PTH 1-84 and PTH “7-84” in the noninvasive diagnosis of renal bone disease. Am J Kidney Dis. 2002;40:348–354
  11. Coen G, Ballanti P, Bonucci E, et al. Bone markers in the diagnosis of low turnover osteodystrophy in haemodialysis patients. Nephrol Dial Transplant. 1998;13:2294–2302
  12. Urena P, de Vernejoul MC. Circulating biochemical markers of bone remodeling in uremic patients. Kidney Int. 1999;55:2141–2156
  13. Chesney RW. Bone mineral density in chronic renal insufficiency and end-stage renal disease: How to interpret the scans. J Pediatr Endocrinol Metab. 2004;17(Suppl 4):1327–1332
  14. Reddi AH. Bone morphogenesis and modeling: Soluble signals sculpt osteosomes in the solid state. Cell. 1997;89:159–161
  15. Hofbauer LC, Heufelder AE. Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology. J Mol Med. 2001;79:243–253
  16. Varga F, Spitzer S, Klaushofer K. Triiodothyronine (T3) and 1,25-dihydroxyvitamin D3 (1,25D3) inversely regulate OPG gene expression in dependence of the osteoblastic phenotype. Calcif Tissue Int. 2004;74:382–387
  17. Huang JC, Sakata T, Pfleger LL, et al. PTH differentially regulates expression of RANKL and OPG. J Bone Miner Res. 2004;19:235–244
  18. Dempster DW, Hughes-Begos CE, Plavetic-Chee K, et al. Normal human osteoclasts formed from peripheral blood monocytes express PTH type 1 receptors and are stimulated by PTH in the absence of osteoblasts. J Cell Biochem. 2005;95:139–148
  19. Avbersek-Luznik I, Balon BP, Rus I, et al. Increased bone resorption in HD patients: Is it caused by elevated RANKL synthesis?. Nephrol Dial Transplant. 2005;20:566–570
  20. Sowa H, Kaji H, Iu MF, et al. Parathyroid hormone-Smad3 axis exerts anti-apoptotic action and augments anabolic action of transforming growth factor beta in osteoblasts. J Biol Chem. 2003;278:52240–52252
  21. Kulkarni NH, Halladay DL, Miles RR, et al. Effects of parathyroid hormone on Wnt signaling pathway in bone. J Cell Biochem. 2005;95:1178–1190
  22. Tobimatsu T, Kaji H, Sowa H, et al. Parathyroid hormone increases beta-catenin levels through Smad3 in mouse osteoblastic cells. Endocrinology. 2006;147:2583–2590
  23. Suda T, Ueno Y, Fujii K, et al. Vitamin D and bone. J Cell Biochem. 2003;88:259–266
  24. Vertino AM, Bula CM, Chen JR, et al. Nongenotropic, anti-apoptotic signaling of 1alpha,25(OH)2-vitamin D3 and analogs through the ligand binding domain of the vitamin D receptor in osteoblasts and osteocytes (Mediation by Src, phosphatidylinositol 3-, and JNK kinases). J Biol Chem. 2005;280:14130–14137
  25. Farach-Carson MC. Bioactive analogs that simulate subsets of biological activities of 1alpha,25(OH)(2)D(3) in osteoblasts. Steroids. 2001;66:357–361
  26. Gurlek A, Pittelkow MR, Kumar R. Modulation of growth factor/cytokine synthesis and signaling by 1alpha,25-dihydroxyvitamin D(3): Implications in cell growth and differentiation. Endocrinol Rev. 2002;23:763–786
  27. Ueno Y, Shinki T, Nagai Y, et al. In vivo administration of 1,25-dihydroxyvitamin D3 suppresses the expression of RANKL mRNA in bone of thyroparathyroidectomized rats constantly infused with PTH. J Cell Biochem. 2003;90:267–277
  28. Takasu H, Sugita A, Uchiyama Y, et al. c-Fos protein as a target of anti-osteoclastogenic action of vitamin D, and synthesis of new analogs. J Clin Invest. 2006;116:528–535
  29. Chen JR, Plotkin LI, Aguirre JI, et al. Transient versus sustained phosphorylation and nuclear accumulation of ERKs underlie anti-versus pro-apoptotic effects of estrogens. J Biol Chem. 2005;280:4632–4638
  30. Quarles LD. FGF23, PHEX, and MEPE regulation of phosphate homeostasis and skeletal mineralization. Am J Physiol Endocrinol Metab. 2003;285:E1–E9
  31. Ritz E, Gross ML. Hyperphosphatemia in renal failure. Blood Purif. 2005;23:6–9
  32. Santos FR, Moyses RM, Montenegro FL, et al. IL-1beta, TNF-alpha, TGF-beta, and bFGF expression in bone biopsies before and after parathyroidectomy. Kidney Int. 2003;63:899–907
  33. Kanatani M, Sugimoto T, Kano J, et al. Effect of high phosphate concentration on osteoclast differentiation as well as bone-resorbing activity. J Cell Physiol. 2003;196:180–189
  34. Larsson T, Marsell R, Schipani E, et al. Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis. Endocrinology. 2004;145:3087–3094
  35. Panda DK, Miao D, Bolivar I, et al. Inactivation of the 25-hydroxyvitamin D 1alpha-hydroxylase and vitamin D receptor demonstrates independent and interdependent effects of calcium and vitamin D on skeletal and mineral homeostasis. J Biol Chem. 2004;279:16754–16766
  36. Zaidi M, Adebanjo OA, Moonga BS, et al. Emerging insights into the role of calcium ions in osteoclast regulation. J Bone Miner Res. 1999;14:669–674
  37. Zaidi M, Moonga BS, Adebanjo OA. Novel mechanisms of calcium handling by the osteoclast: A review hypothesis. Proc Assoc Am Physicians. 1999;111:319–327
  38. Lorget F, Kamel S, Mentaverri R, et al. High extracellular calcium concentrations directly stimulate osteoclast apoptosis. Biochem Biophys Res Commun. 2000;268:899–903
  39. Kanatani M, Sugimoto T, Kanzawa M, et al. High extracellular calcium inhibits osteoclast-like cell formation by directly acting on the calcium-sensing receptor existing in osteoclast precursor cells. Biochem Biophys Res Commun. 1999;261:144–148
  40. Xu J, Wang C, Han R, et al. Evidence of reciprocal regulation between the high extracellular calcium and RANKL signal transduction pathways in RAW cell derived osteoclasts. J Cell Physiol. 2005;202:554–562
  41. Eastwood JB. Quantitative bone histology in 38 patients with advanced renal failure. J Clin Pathol. 1982;35:125–134
  42. Mora Palma FJ, Ellis HA, Cook DB, et al. Osteomalacia in patients with chronic renal failure before dialysis or transplantation. Q J Med. 1983;52:332–348
  43. Coen G, Mazzaferro S, Ballanti P, et al. Renal bone disease in 76 patients with varying degrees of predialysis chronic renal failure: A cross-sectional study. Nephrol Dial Transplant. 1996;11:813–819
  44. Dahl E, Nordal KP, Attramadal A, et al. Renal osteodystrophy in predialysis patients without stainable bone aluminum (A cross-sectional bone-histomorphometric study). Acta Med Scand. 1988;224:157–164
  45. Hernandez D, Concepcion MT, Lorenzo V, et al. Adynamic bone disease with negative aluminum staining in predialysis patients: Prevalence and evolution after maintenance dialysis. Nephrol Dial Transplant. 1994;9:517–523
  46. Shin SK, Kim DH, Kim HS, et al. Renal osteodystrophy in pre-dialysis patients: Ethnic difference?. Perit Dial Int. 1999;19(Suppl 2):S402–S407
  47. Spasovski GB, Bervoets AR, Behets GJ, et al. Spectrum of renal bone disease in end-stage renal failure patients not yet on dialysis. Nephrol Dial Transplant. 2003;18:1159–1166
  48. Torres A, Lorenzo V, Hernandez D, et al. Bone disease in predialysis, hemodialysis, and CAPD patients: Evidence of a better bone response to PTH. Kidney Int. 1995;47:1434–1442
  49. Malluche HH. Aluminium and bone disease in chronic renal failure. Nephrol Dial Transplant. 2002;17(Suppl 2):21–24
  50. Kurz P, Monier-Faugere MC, Bognar B, et al. Evidence for abnormal calcium homeostasis in patients with adynamic bone disease. Kidney Int. 1994;46:855–861
  51. London GM, Marty C, Marchais SJ, et al. Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol. 2004;15:1943–1951
  52. Block GA, Port FK. Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: Recommendations for a change in management. Am J Kidney Dis. 2000;35:1226–1237

PII: S1548-5595(06)00172-8

doi: 10.1053/j.ackd.2006.10.010

Advances in Chronic Kidney Disease
Volume 14, Issue 1 , Pages 27-36 , January 2007

Article Tools

* Image Usage & Resolution